ALS-008176
Sponsors
Alios Biopharma Inc., Janssen Research & Development, LLC
Conditions
HealthyRespiratory Syncytial Virus Infections
Phase 1
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers
CompletedNCT01906164
Start: 2013-05-31End: 2013-11-30Updated: 2017-10-31
A Study of ALS-008176 in Infants Hospitalized With RSV
CompletedNCT02202356
Start: 2014-07-23End: 2018-02-15Updated: 2025-02-03
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
CompletedNCT02231671
Start: 2014-08-31End: 2014-11-30Updated: 2017-10-31
Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
CompletedNCT02833831
Start: 2016-06-02End: 2017-02-24Updated: 2025-02-03
Phase 2
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
CompletedNCT02094365
Start: 2014-03-31End: 2014-07-31Updated: 2025-02-03
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
CompletedNCT02673476
Start: 2016-02-29End: 2016-10-31Updated: 2025-02-04